Immutep Commences Patient Dosing in Additional TACTI-mel Cohort
March 21 2018 - 6:29PM
Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the
“Company”) has announced the initiation of patient dosing in the
new cohort of the TACTI-mel (Two ACTive Immunotherapies in
melanoma) Phase 1 clinical trial. This clinical study is
evaluating the combination of Immutep’s lead immunotherapy product
candidate eftilagimod alpha (“efti” or “IMP321”) with pembrolizumab
(KEYTRUDA®) in unresectable or metastatic melanoma patients in
Australia.
The additional cohort consists of six patients that will receive
30 mg of efti in combination with pembrolizumab starting at cycle
one of pembrolizumab. Patients will be treated for up to 12 months.
Yesterday the first patient in this cohort received their first
dose of the two drugs. Safety assessment is the main objective of
this study.
“This additional cohort of the ongoing TACTI-mel clinicial trial
is very important to the clinical development of efti, especially
in the light of our new collaboration study announced on 12th of
March 2018, as we are now dosing efti at cycle one in combination
with KEYTRUDA® with the highest dose and for a 12-month duration,”
said Dr. Frédéric Triebel, Immutep’s Chief Scientific Officer and
Chief Medical Officer. “We look forward to presenting
additional data from the TACTI-mel study during the middle of this
calendar year as we hope it will further support our hypothesis
that combining an antigen-presenting cell activator (efti) with a
checkpoint inhibitor (KEYTRUDA®) results in a therapeutic synergy
and a potential benefit over checkpoint inhibitor monotherapy.”
About Immutep
Immutep is listed on the Australian Securities Exchange (IMM),
and on the NASDAQ (IMMP) in the U.S.
For further information please visit
www.immutep.com or contact:
U.S. Investors:Jay Campbell,
Vice President of Business Development and Investor Relations,
Immutep Limited+1 (917) 860-9404; jay.campbell@immutep.com
Australian
Investors/Media:Matthew Gregorowski, Citadel-MAGNUS+61 2
8234 0105; mgregorowski@citadelmagnus.com
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immutep (NASDAQ:IMMP)
Historical Stock Chart
From Jul 2023 to Jul 2024